(+)-JQ1

For research use only. Not for use in humans.

Catalog No.S7110

203 publications

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's (+)-JQ1 has been cited by 203 publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  NVPLTm1pS2WubDDWbYFjcWyrdImgRZN{[Xl? NGDadYozPTBxNUCwM|ExODBibl2= NUHFd4lkOjRxNEivO|IhcA>? MX\EUXNQ M3\l[IlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NFvqZ2MzPjdyN{i4NS=>
BCPAP MoD5R4VtdCCYaXHibYxqfHliQYPzZZk> NHrFcGgzPTBxNUCwM|ExODBibl2= Mm[2NlQwPDhxN{KgbC=> M123fGROW09? MWfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy Ml3uNlY4ODd6OEG=
K1  MWnD[YxtKEO7Y3zlJGF{e2G7 NXva[Y5pOjVyL{WwNE8yODByIH7N MYi3NkBp NH:3SGVFVVOR NXXFellx[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl Mo\nNlY4ODd6OEG=
BCPAP NY[yR45RS2WubDDDfYNt\SCDc4PhfS=> M4HqUFI2OC93MECvNVAxOCCwTR?= NU\mWYFYPzJiaB?= M3qwbmROW09? NILmOHZienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS|EheGijc3W= Mo[yNlY4ODd6OEG=
Hep3B NFrLdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;kS5MxNTFyIN88US=> MVK1JIQ> MWPEUXNQ MXvJR|UxRTBwMEig{txO NH\KdJIzPjV5NUG2Oy=>
HCCLM3 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXySXR1OC1zMDFOwG0> MYW1JIQ> NEfRTIZFVVOR MYDJR|UxRTBwMUSg{txO NInaRoEzPjV5NUG2Oy=>
HuH7 NGPnZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfDNE0yOCEQvF2= MnXJOUBl NGDCWZBFVVOR NGfRSVFKSzVyPUCuNlEh|ryP Mnj2NlY2PzVzNke=
HepG2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:wMVExKM7:TR?= M1TV[|Uh\A>? M2O1VWROW09? MkfITWM2OD1yLkO0JO69VQ>? NIfCemMzPjV5NUG2Oy=>
SMMC7721 MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS3NE0yOCEQvF2= MYm1JIQ> MXnEUXNQ NGHV[VRKSzVyPUCuOFEh|ryP MnvMNlY2PzVzNke=
BEL7402 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTLVVlsOC1zMDFOwG0> NWL0eWdZPSCm MnTtSG1UVw>? MUDJR|UxRTBwNEeg{txO NGHlfHEzPjV5NUG2Oy=>
MHCC97H MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HrSlAuOTBizszN NWnteVgzPSCm MmfLSG1UVw>? NV7ISpBEUUN3ME2wMlQyKM7:TR?= NXX2N4Y3OjZ3N{WxOlc>
Hep3B NVnub2x6S2WubDDDfYNt\SCDc4PhfS=> MUiwMlEwOC53L{KuOUDPxE1? NXj5VGpwPDhiaB?= M3\VUmROW09? MWHs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> M4L1T|I3PTd3MU[3
HCCLM3 NFrxZ4tE\WyuIFP5Z4xmKEG|c3H5 M4judlAvOS9yLkWvNk42KM7:TR?= MVW0PEBp M2X6SGROW09? MlvrcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh MUmyOlU4PTF4Nx?=
Hep3B MkTQRZBweHSxc3nzJGF{e2G7 M{fmbVAvOS9yLkWvNk42KM7:TR?= MW[0PEBp NGnPPXpFVVOR MXPhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli MWOyOlU4PTF4Nx?=
HCCLM3 MYTBdI9xfG:|aYOgRZN{[Xl? M2[0ZlAvOS9yLkWvNk42KM7:TR?= M2e3d|Q5KGh? NWHyeYs{TE2VTx?= MXPhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli M3HhTlI3PTd3MU[3
A549 NX\5Tm41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjKSIMxNjFvMUCg{txO NGfoSWU4OiCq MojLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWeyOlQyPTJ{NR?=
H157 NWH6XXlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37PWFAvOS1zMDFOwG0> NYDCVVY6PzJiaB?= MXvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXWyOlQyPTJ{NR?=
H1299 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGwMlEuOTBizszN NHTkOpo4OiCq MXrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUOyOlQyPTJ{NR?=
A549 NWTEUY9GTnWwY4Tpc44hSXO|YYm= NYHXbZJFOS9{LkWvOUDPxE1? MVuxNkBp MV9CpJdm[WuueTDk[YNz\WG|ZXSgRoNtNTJibHX2[Yx{ M4HWclI3PDF3MkK1
H1299 NHzlN5dHfW6ldHnvckBCe3OjeR?= MXWxM|IvPS93IN88US=> NXPnOYI3OTJiaB?= MUpCpJdm[WuueTDk[YNz\WG|ZXSgRoNtNTJibHX2[Yx{ MkLCNlY1OTV{MkW=
H157 NHrWVYxHfW6ldHnvckBCe3OjeR?= MUexM|IvPS93IN88US=> MYqxNkBp M{O4N4Rm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?= MoHBNlY1OTV{MkW=
H1299 NHzSc3pHfW6ldHnvckBCe3OjeR?= NE\2THQyNzJwNT:1JO69VQ>? M3PZXVEzKGh? M3vtOIRm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?= NHHGcXIzPjRzNUKyOS=>
C8161 NIPENWdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWO3e5YxOC1{IN88US=> MV:0JIQ> NFG5Tm1FVVOR M4S2W4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFj1c4czPjN7N{KyNy=>
Mel285 MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV[wMVIh|ryP M3PVclQh\A>? M2[yUmROW09? MmDz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkT2NlY{QTd{MkO=
Mel290 MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVGwMVIh|ryP NFzPd4I1KGR? MXHEUXNQ Ml6y[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmP0NlY{QTd{MkO=
92.1 M1jtVmNmdGxiVnnhZoltcXS7IFHzd4F6 NHvVZpQxNTJizszN NGPjWnE1KGR? MmnpSG1UVw>? Ml3X[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHWy[YUzPjN7N{KyNy=>
Omm1.3 Ml7PR4VtdCCYaXHibYxqfHliQYPzZZk> M{PlZlAuOiEQvF2= M4TwWlQh\A>? MWfEUXNQ Moe4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWCyOlM6PzJ{Mx?=
Mel202 NIDnclNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXywMVIh|ryP NVzTXYplPCCm MUHEUXNQ NYT0Zot6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFrlZnIzPjN7N{KyNy=>
Mel270 M360b2NmdGxiVnnhZoltcXS7IFHzd4F6 NILQNJIxNTJizszN NU\DfZZqPCCm MmXCSG1UVw>? MWTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{HvUFI3Ozl5MkKz
Omm1 M1jON2NmdGxiVnnhZoltcXS7IFHzd4F6 NWjydoxZOC1{IN88US=> NGHUbmY1KGR? NWLs[JhWTE2VTx?= MmCz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mn;VNlY{QTd{MkO=
92.1 M3W4[WFxd3C2b4Ppd{BCe3OjeR?= NIC3bZg2ODBibl2= MWC0PEBp NFHHOWlFVVOR MU\pcoR2[2W|IHHwc5B1d3Orcx?= M4f2blI3Ozl5MkKz
Omm1.3 MVPBdI9xfG:|aYOgRZN{[Xl? NXTqOnN3PTByIH7N M4XpVlQ5KGh? NU\s[Vd1TE2VTx?= Mn3rbY5lfWOnczDhdI9xfG:|aYO= NYrPdGlqOjZ|OUeyNlM>
92.1 NGDKOIxE\WyuIFP5Z4xmKEG|c3H5 M4Cwd|UxOCCwTR?= M37DR|I1NzR6L{eyJIg> MULEUXNQ MYjpcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? NULqSo1yOjZ|OUeyNlM>
Omm1.3 MnXhR4VtdCCFeXPs[UBCe3OjeR?= MojoOVAxKG6P MnzKNlQwPDhxN{KgbC=> MlywSG1UVw>? NXfKVVVVcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= Mn\yNlY{QTd{MkO=
A549 NEHUc3hHfW6ldHnvckBCe3OjeR?= NELnOJoyODBxNECwM|ExODBibl2= MlG1NlQhcA>? MVz1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy NFrN[XozPjJzMkG5PS=>
MCF-7 NXm3NYVxTnWwY4Tpc44hSXO|YYm= NYmyblQxOTByL{SwNE8yODByIH7N NGXGNJIzPCCq M2DHRpVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? MUmyOlIyOjF7OR?=
HEK293 M2[4OmZ2dmO2aX;uJGF{e2G7 NHz1RVgyODBxNECwM|ExODBibl2= NYGz[pZUOjRiaB?= M2HOUJVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? MmjkNlYzOTJzOUm=
858 M{jDOWNmdGxiVnnhZoltcXS7IFHzd4F6 M2rpblAuOSEQvF2= MYG1JIQ> M1q0VmROW09? Ml\4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MonZNlYzODZ|M{O=
DDR2L63V NWfxcY5GS2WubDDWbYFjcWyrdImgRZN{[Xl? MmjRNE0yKM7:TR?= M32zOVUh\A>? MYHEUXNQ NHO3WWll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MX[yOlIxPjN|Mx?=
BE(2)-C MoOxR4VtdCCYaXHibYxqfHliQYPzZZk> MV:xJO69VQ>? NGL2cJEyNTRiZB?= MX\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> NWLzT|NHOjZyNke0OlQ>
IMR-32 MnnuR4VtdCCYaXHibYxqfHliQYPzZZk> NW\2O4JxOSEQvF2= M3jmWlEuPCCm M2n5c4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NWnJVJl6OjZyNke0OlQ>
JF M4PscGNmdGxiVnnhZoltcXS7IFHzd4F6 M3PIOlEh|ryP NIDrN3cyNTRiZB?= NYj6bHY2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M3jPWFI3ODZ5NE[0
BE(2)-M17 MlrtR4VtdCCYaXHibYxqfHliQYPzZZk> Ml72NUDPxE1? MUexMVQh\A>? NGiy[|Vl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MkKxNlYxPjd2NkS=
SK-N-SH Mlr5R4VtdCCYaXHibYxqfHliQYPzZZk> M{fQ[VEh|ryP MYCxMVQh\A>? M3KxVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MXyyOlA3PzR4NB?=
SK-N-DZ  NV;RNGh3S2WubDDWbYFjcWyrdImgRZN{[Xl? MWCxJO69VQ>? MnHJNU01KGR? M{ixOoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MnXwNlYxPjd2NkS=
HMC-1.1  NIfTd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nxNFUuPTByMDDuUS=> MonBOFghcA>? Moi1SG1UVw>? NWHVdGhkcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1n4fVI3ODV3M{Cz
HMC-1.2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWOU02ODByIH7N MYS0PEBp MmjzSG1UVw>? MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVr2bJQzOjZyNUWzNFM>
ROSA KIT WT  M1jZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXm1MVUxODBibl2= NHLCNmk1QCCq NVHjfHFWTE2VTx?= NFSxeFdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXGyOlA2PTNyMx?=
ROSA KIT D816V NIPKU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:5UVI2PS13MECwJI5O MWK0PEBp M4PKdmROW09? Mk\2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHL4dlEzPjB3NUOwNy=>
HMC-1.1  MWrBdI9xfG:|aYOgRZN{[Xl? NXq0VXhUOjByLUWwNFAhdk1? MUC0PEBp MXPEUXNQ NYrzW4dMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVuyOlA2PTNyMx?=
HMC-1.2 MWLBdI9xfG:|aYOgRZN{[Xl? NGTF[3IzODBvNUCwNEBvVQ>? NULi[pRqPDhiaB?= M4POS2ROW09? NHfTeYRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NH;N[o4zPjB3NUOwNy=>
ROSA KIT WT  NEmyRXlCeG:ydH;zbZMhSXO|YYm= NF35SnkzODBvNUCwNEBvVQ>? MUO0PEBp M4jufmROW09? MmjQbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MViyOlA2PTNyMx?=
ROSA KIT D816V MYDBdI9xfG:|aYOgRZN{[Xl? M{fEWlIxOC13MECwJI5O MYS0PEBp NIXvVFdFVVOR MVTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2\xR|I3ODV3M{Cz
494H MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWW3NkBp NHS1R|FFVVOR M4TuUWlEPTB;MD6xNlLDuTBwMEC0JO69VQ>? MWiyOVk1PDV4Nh?=
493H M{fKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu3NkBp M1TEVWROW09? MWjJR|UxRTBwMES3xtExNjByOTFOwG0> MYGyOVk1PDV4Nh?=
716H MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\OdVczKGh? M{HSSmROW09? NViyWVhmUUN3ME2wMlIyOsLzMD6wN|Qh|ryP MlTmNlU6PDR3Nk[=
148I MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXqO|IhcA>? NWroV45ITE2VTx?= NIfOV|dKSzVyPUCuNlg1yrFyLkCzOUDPxE1? MkTuNlU6PDR3Nk[=
98Sc M3XtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7PTHE4OiCq NEHiXFhFVVOR NF7yOZdKSzVyPUCuNVE2yrFyLkCwOEDPxE1? MYGyOVk1PDV4Nh?=
89R MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV63NkBp NHLKRVZFVVOR NV3qfGpPUUN3ME2wMlEzPsLzMD6wNFMh|ryP MnfINlU6PDR3Nk[=
494L MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PE[lczKGh? NWTpUZZ[TE2VTx?= MoDhTWM2OD1yLkOxO:KyOC5yMUKg{txO M4ewbFI2QTR2NU[2
493L MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO5fGo4OiCq M3XOZmROW09? MWnJR|UxRTBwMEWwxtExNjBzMTFOwG0> NV6z[Zl4OjV7NES1OlY>
148L MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[3NkBp M1TPbWROW09? M1r3cWlEPTB;MD6xOFbDuTBwMEG3JO69VQ>? M3P3Z|I2QTR2NU[2
98L NFTVPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG3NkBp MkXDSG1UVw>? Mnr4TWM2OD1yLkOwPeKyOC5yMkmg{txO NY[xWmdxOjV7NES1OlY>
OS17 M3HnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDWO|IhcA>? MYnEUXNQ MljiTWM2OD1yLkC3PeKyOC5yMEOg{txO NV7H[JNZOjV7NES1OlY>
OS9 M4D3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4iyT|czKGh? Mni2SG1UVw>? MXfJR|UxRTBwNEC2xtExNjB{ODFOwG0> M4TVXVI2QTR2NU[2
MG63 NVXVT4ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[5O|IhcA>? M3m4[WROW09? MmPxTWM2OD1yLkGxOOKyOC5yMkWg{txO MV:yOVk1PDV4Nh?=
SAOS2 M3K5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLPNot{PzJiaB?= MV7EUXNQ NIfBTo9KSzVyPUCuNlE4yrFyLkCwN{DPxE1? NUjQNZl{OjV7NES1OlY>
U2OS NYi5O2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[3NkBp NWTKUo9pTE2VTx?= M1yyb2lEPTB;MD6xPVjDuTBwMEC4JO69VQ>? M1fycFI2QTR2NU[2
SJSA-1 M2ftNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vhbVczKGh? M13ue2ROW09? M3fFWGlEPTB;MD6xNFDDuTBwMEGwJO69VQ>? MoqyNlU6PDR3Nk[=
494H MXnBdI9xfG:|aYOgRZN{[Xl? MUewMlI2NzBwNT:xMlAh|ryP M{X3TlI1KGh? MYjEUXNQ MYXpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MViyOVk1PDV4Nh?=
148I MojZRZBweHSxc3nzJGF{e2G7 MoLvNE4zPS9yLkWvNU4xKM7:TR?= NFPrVmMzPCCq NEPOd2lFVVOR M2XHTYlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? NIDjSGUzPTl2NEW2Oi=>
OS17 NV[xfIVCSXCxcITvd4l{KEG|c3H5 NXfqWol6OC5{NT:wMlUwOS5yIN88US=> NF2zUmgzPCCq M1voTWROW09? MYfpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MmT5NlU6PDR3Nk[=
494H NEP4[4tCeG:ydH;zbZMhSXO|YYm= Mlu3NgKBkc7:TR?= NHrV[201QCCq M2XrV2ROW09? MmPsbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 NGLic3YzPTl2NEW2Oi=>
148I M1vJSGFxd3C2b4Ppd{BCe3OjeR?= NXfZfmJkOeLCid88US=> M4f1dVQ5KGh? MY\EUXNQ MnK4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 MnjONlU6PDR3Nk[=
OS17 NHnYTWZCeG:ydH;zbZMhSXO|YYm= MYmx5qCK|ryP MnXSOFghcA>? MY\EUXNQ MXzpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= NIDlb20zPTl2NEW2Oi=>
MOLM13 M4TNcmFxd3C2b4Ppd{BCe3OjeR?= MofLNlUxKG6P MVu0PEBp M3HhRWROW09? MYHpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? MYqyOVA2Ozh{NR?=
MV4-11  NV;RfG9{SXCxcITvd4l{KEG|c3H5 NETr[FQzPTBibl2= M4myclQ5KGh? MVnEUXNQ MV;pcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? NULaTHRtOjVyNUO4NlU>
MOLM13 MVzGeY5kfGmxbjDBd5NigQ>? MnrhNlUxKG6P NXvqbppiOjRiaB?= NX;ReIgxTE2VTx?= Mlnz[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS NH\rfXYzPTB3M{iyOS=>
MV4-11  M1rP[GZ2dmO2aX;uJGF{e2G7 NVnnSlE2OjVyIH7N M13t[VI1KGh? MWLEUXNQ MVLlcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB? M2q1bFI2ODV|OEK1
MOLM13 M4[zc2Fxd3C2b4Ppd{BCe3OjeR?= MWSyOVAhdk1? NU\MNYN[PDhiaB?= MmnBSG1UVw>? NHTXTZBqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk MonTNlUxPTN6MkW=
MV4-11  MkDiRZBweHSxc3nzJGF{e2G7 Mn\mNlUxKG6P M4LxOFQ5KGh? NEns[3dFVVOR MYPpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheG:wYYTpcolj NWi4UWxxOjVyNUO4NlU>
Hela MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NITteG4xNTVyMDDuUS=> NWPLSWVXPzJiaB?= NWrCWmQyTE2VTx?= NFe2flVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXTmb2IyOjVyMEmyPVU>
HBL-1 MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEDMPWIxNTVyMDDuUS=> NWraN3R2PzJiaB?= MXrEUXNQ MXTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnzzNlUxODl{OUW=
HLY-1 M4\QR2NmdGxiVnnhZoltcXS7IFHzd4F6 MYOwMVUxOCCwTR?= Ml;nO|IhcA>? NXmwfpV5TE2VTx?= NF7P[Hdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3;od|I2ODB7Mkm1
OCI-Ly3 NXf0RoIxS2WubDDWbYFjcWyrdImgRZN{[Xl? MmXwNE02ODBibl2= MkH6O|IhcA>? M4DRfmROW09? MWfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWjOUHFpOjVyMEmyPVU>
OCI-Ly10 M1PT[2NmdGxiVnnhZoltcXS7IFHzd4F6 Mk\PNE02ODBibl2= MYm3NkBp NGOydnhFVVOR NFK5T5Jl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M4GydVI2ODB7Mkm1
SU-DHL-4 MkfPR4VtdCCYaXHibYxqfHliQYPzZZk> NEnpSW4xNTVyMDDuUS=> M1T6flczKGh? NU\SSXhTTE2VTx?= MoDF[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mo\XNlUxODl{OUW=
SU-DHL-5 M2jVPWNmdGxiVnnhZoltcXS7IFHzd4F6 MYKwMVUxOCCwTR?= NIX0OIE4OiCq NF6yfpdFVVOR NGnIOHhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVGyOVAxQTJ7NR?=
SU-DHL-6 M2m5OGNmdGxiVnnhZoltcXS7IFHzd4F6 MmHHNE02ODBibl2= M4XRblczKGh? NILIOnZFVVOR NX3USWFw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NW\6W4tyOjVyMEmyPVU>
SU-DHL-10 NWraV5JTS2WubDDWbYFjcWyrdImgRZN{[Xl? Ml\uNE02ODBibl2= MlXCO|IhcA>? MYDEUXNQ M33QcYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3PQeVI2ODB7Mkm1
RC-K8 MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmrTNE02ODBibl2= MmSxO|IhcA>? NEnmbFdFVVOR NUntR|M3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1;acFI2ODB7Mkm1
OCI-Ly8 NH[3XGtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF7aUJYxNTVyMDDuUS=> M33rblczKGh? NFrQS29FVVOR Mn7y[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2XMUVI2ODB7Mkm1
OCL-Ly18 MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mlv0NE02ODBibl2= NXTHU4wzPzJiaB?= MVrEUXNQ M1roPIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWCyOVAxQTJ7NR?=
OCI-Ly3 MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrxVHhROTd{L{K1NE82ODBibl2= M1K2SFIwPyCm MmnNSG1UVw>? MkLlbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= M1fpdVI2ODB7Mkm1
OCI-Ly8 NUT4N3dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlKxNVczNzJ3MD:1NFAhdk1? M3Pq[FIwPyCm NUL6dpRVTE2VTx?= MUfpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi MYSyOVAxQTJ7NR?=
SU-DHL-4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz1RWwyPzJxMkWwM|UxOCCwTR?= MXqyM|ch\A>? M1nlN2ROW09? NEf1PXdqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg MV:yOVAxQTJ7NR?=
SU-DHL-10 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1izR|E4Oi9{NUCvOVAxKG6P MWGyM|ch\A>? MnLqSG1UVw>? NHvkW|BqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NWDVclJ2OjVyMEmyPVU>
OCI-Ly3 M{LVSGFxd3C2b4Ppd{BCe3OjeR?= MYWxO|IwOjVyIH7N MnK3O4Q> MYnEUXNQ MnnObY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MWOyOVAxQTJ7NR?=
OCI-Ly8 M4\OOWFxd3C2b4Ppd{BCe3OjeR?= NUDmO3ZGOTd{L{K1NEBvVQ>? NFnrfWg4\A>? NWq0UVh1TE2VTx?= MXzpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= NV;5WZlLOjVyMEmyPVU>
SU-DHL-4 NWqwVYZwSXCxcITvd4l{KEG|c3H5 NYHhfHMyOTd{L{K1NEBvVQ>? MkPjO4Q> MoDFSG1UVw>? M4HHVIlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> M3mzVVI2ODB7Mkm1
SU-DHL-10 MXHBdI9xfG:|aYOgRZN{[Xl? MYKxO|IwOjVyIH7N NHnQTGg4\A>? MU\EUXNQ NYW3[JpOcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 M3zSU|I2ODB7Mkm1

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; 

PubMed: 26119999     


The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. 

c-Myc; 

PubMed: 23792448     


PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. 

p27; 

PubMed: 23792448     


Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.

26119999 23792448
Growth inhibition assay
Cell viability; 

PubMed: 23792448     


PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control. 

23792448
Immunofluorescence
GM130; 

PubMed: 29074567     


Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. 

MHC / EdU; 

PubMed: 28733670     


C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.

29074567 28733670
In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A
Smiles CC1=C(C)C2=C(S1)[N]3C(=NN=C3C(CC(=O)OC(C)(C)C)N=C2C4=CC=C(Cl)C=C4)C

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID